Morningstar Direct Morningstar Office Cloud Morningstar Advisor Workstation Morningstar Data PitchBook Morningstar Enterprise Components Money Management Morningstar Retirement Manager Morningstar Managed Portfolios Morningstar Indexes Conference All Products & Services Morningstar assigns star ratings based on an analyst’s estimate of a stock's fair value. Four components drive the Star Rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases. Data from multiple studies, including results in the outpatient administration setting and Headline Source Date/Time; Bristol-Myers Gets FDA Priority Review for Opdivo/Yervoy for Non-Small Cell Lung Cancer: DJ: 01-15-20 | 07:38 AM EST: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
BRISTOL-MYERS SQUIBB COMPANY : Historical chart, prices and data share BRISTOL-MYERS SQUIBB COMPANY | BMY | Nyse Bristol-Myers Squibb | Fortune © 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy (Your California Privacy Rights
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the Learn about DIS with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on DIS. SHANGHAI--Drugs that failed to make it to the market in the U.S. and elsewhere are finding new life in China. In 2013, Bristol-Myers Squibb Co. stopped global trials of a first-line | March 29, 2016 LOS ANGELES, CA / ACCESSWIRE / February 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb | February 28, 2018
Learn about DIS with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on DIS. SHANGHAI--Drugs that failed to make it to the market in the U.S. and elsewhere are finding new life in China. In 2013, Bristol-Myers Squibb Co. stopped global trials of a first-line | March 29, 2016
She also led various clinical development programs at Pfizer and Bristol-Myers Squibb. Dr. Countouriotis received her residency training at University of California, Los Angeles as well as at Fred